Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Inventory (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Inventory for 15 consecutive years, with $12.9 million as the latest value for Q1 2026.

  • For Q1 2026, Inventory fell 10.29% year-over-year to $12.9 million; the TTM value through Mar 2026 reached $12.9 million, down 10.29%, while the annual FY2025 figure was $12.9 million, 3.67% up from the prior year.
  • Inventory hit $12.9 million in Q1 2026 for Corcept Therapeutics, roughly flat from $12.9 million in the prior quarter.
  • Across five years, Inventory topped out at $14.4 million in Q1 2025 and bottomed at $5.1 million in Q1 2022.
  • Average Inventory over 5 years is $8.9 million, with a median of $7.7 million recorded in 2023.
  • Year-over-year, Inventory soared 99.83% in 2025 and then decreased 10.29% in 2026.
  • Corcept Therapeutics' Inventory stood at $6.1 million in 2022, then increased by 26.72% to $7.7 million in 2023, then skyrocketed by 60.57% to $12.4 million in 2024, then increased by 3.67% to $12.9 million in 2025, then rose by 0.17% to $12.9 million in 2026.
  • According to Business Quant data, Inventory over the past three periods came in at $12.9 million, $12.9 million, and $12.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.